Edition:
United States

TapImmune Inc (TPIV.OQ)

TPIV.OQ on NASDAQ Stock Exchange Capital Market

7.55USD
4:00pm EDT
Change (% chg)

$-0.24 (-3.08%)
Prev Close
$7.79
Open
$7.85
Day's High
$7.89
Day's Low
$7.51
Volume
6,339
Avg. Vol
91,469
52-wk High
$13.54
52-wk Low
$2.60

Latest Key Developments (Source: Significant Developments)

Tapimmune Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Treating Triple-Negative Breast Cancer
Tuesday, 12 Dec 2017 06:30am EST 

Dec 12 (Reuters) - Tapimmune Inc ::TAPIMMUNE ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL FOR TREATING TRIPLE-NEGATIVE BREAST CANCER FUNDED BY U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE INC - 280-PATIENT PHASE 2 TRIAL, SPONSORED BY MAYO CLINIC, RECEIVED $13.3 MILLION IN GRANT FUNDING FROM U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE - ‍INTERIM IMMUNOGENICITY RESULTS FROM ONGOING STUDY EVALUATING TPIV200 IN RANDOMIZED DOSING TRIAL IN TNBC ANTICIPATED IN FIRST HALF OF 2018.  Full Article

Tapimmune Q3 loss earnings per share $0.39‍​
Wednesday, 15 Nov 2017 04:05pm EST 

Nov 15 (Reuters) - Tapimmune Inc :Tapimmune provides third quarter 2017 corporate and clinical update.Tapimmune Inc - qtrly loss earnings per share $0.39‍​.  Full Article

TapImmune says 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​
Tuesday, 14 Nov 2017 06:30am EST 

Nov 14 (Reuters) - TapImmune Inc ::TapImmune Inc - 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​.TapImmune - ‍enrolled final patient in randomized Phase 2 clinical study of novel T-cell vaccine candidate TPIV200.TapImmune Inc - ‍look forward to reporting interim immunogenicity results in first half of 2018 from TPIV200 study​.  Full Article

TapImmune appoints Peter Hoang as president and CEO
Monday, 25 Sep 2017 06:30am EDT 

Sept 25 (Reuters) - TapImmune Inc :TapImmune appoints Peter Hoang as president and chief executive officer.TapImmune Inc - ‍Glynn Wilson, who was recently re-appointed chairman, will now serve as as strategic advisor​.TapImmune Inc - with Hoang appointment, board of directors has expanded from six to seven members.TapImmune Inc - Hoang has also been appointed as a member of TapImmune's board of directors.  Full Article

Tapimmune files for‍​ resale of 4.4 mln shares of common stock held by selling stockholders
Wednesday, 20 Sep 2017 04:45pm EDT 

Sept 20 (Reuters) - Tapimmune Inc :Tapimmune Inc - Files for‍​ resale 4.4 million shares of common stock which are currently held by selling stockholders - SEC filing.  Full Article

TapImmune to raise $6.82 million in a private placement
Thursday, 22 Jun 2017 09:18am EDT 

June 22 (Reuters) - Tapimmune Inc :Tapimmune inc. Enters into definitive agreements to raise $6.82 million in a private placement from accredited investors and from the exercise of warrants by existing institutional investors.Tapimmune inc - in private placement transaction, tapimmune has agreed to sell 1.5 million shares of common stock for $3.97 per share.  Full Article

Tapimmune says John Bonfiglio resigns as chief operating officer
Friday, 28 Apr 2017 04:05pm EDT 

April 28 (Reuters) - Tapimmune Inc -:Tapimmune announces change in management and board of directors.Tapimmune -on april 27, 2017, Dr. John Bonfiglio resigned as chief operating officer, president and director of Tapimmune to pursue other opportunities.Tapimmune Inc - in connection with Bonfiglio's resignation, size of board was reduced from seven members to six members.Tapimmune Inc - Wilson, was appointed to serve as company's president due to vacancy created by bonfiglio's resignation.  Full Article

TapImmune announces fully funded phase 2 clinical study of HER2-targeted vaccine
Tuesday, 14 Mar 2017 09:15am EDT 

TapImmune Inc : Announces fully funded phase 2 clinical study of HER2-targeted vaccine in early breast cancer . Study is expected to begin in 2017 . Collaborators at Mayo Clinic, received $3.7 million grant from U.S. DoD to conduct phase 2 clinical study on TapImmune's HER2/neu-targeted T-cell vaccine .Co will be funded for providing manufactured product for this trial.  Full Article

TapImmune files to register for resale about 2.7 mln shares of co's common stock
Thursday, 19 Jan 2017 08:23am EST 

TapImmune Inc : TapImmune Inc files to register for resale about 2.7 million shares of co's common stock currently held by the selling stockholders - sec filing .TapImmune - in addition about 5 million shares of co's common stock issuable upon exercise of warrants held by the selling shareholders.  Full Article

Tapimmune launches Phase 2 ovarian cancer trial in platinum-sensitive patients
Tuesday, 10 Jan 2017 09:15am EST 

Tapimmune Inc :Tapimmune launches Phase 2 ovarian cancer trial in platinum-sensitive patients.  Full Article

BRIEF-Tapimmune And Marker Therapeutics Announce Entry Into Merger Agreement

* TAPIMMUNE AND MARKER THERAPEUTICS ANNOUNCE ENTRY INTO MERGER AGREEMENT, CREATING A TRANSFORMATIONAL IMMUNO-ONCOLOGY PLATFORM

No consensus analysis data available.